Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
This study is a prospective cohort study aimed at comparing the efficacy and safety of RALOX-HAIC and FOLFOX-HAIC in the treatment of hepatocellular carcinoma. It is planned to enroll 1115 patients with BCLC Stage B or C hepatocellular carcinoma, who will receive FOLFOX-HAIC or RALOX-HAIC treatment.
Hepatocellular Carcinoma
DRUG: hepatic artery infusion chemotherapy
Progression-Free Survival (PFS), Defined as the time from the date of enrollment to the date of any recorded tumor progression or death from any cause., 2 years|Time to Progression (TTP), Defined as the time from the date of enrollment to the date of any recorded tumor progression., 2 years|adverse events, Incidence and grading of adverse events (AE) and serious adverse events (SAE)., 2 years
Overall Survival (OS), Defined as the time from the start of patient enrollment to death from any cause., 2 years|Objective Response Rate (ORR), Defined as the percentage of subjects with the best response of CR or PR among all subjects in the analysis dataset, from the first dose to the first record of disease progression or death from any cause (whichever occurs first), using the response evaluation criteria in solid tumors (RECIST 1.1 and mRECIST standards)., 2 years|Disease Control Rate (DCR), Defined as the percentage of subjects with the best response of CR, PR, or SD among all subjects in the analysis dataset, from the first dose to the first record of disease progression or death from any cause (whichever occurs first), using the response evaluation criteria in solid tumors (RECIST 1.1 and mRECIST standards)., 2 years
This study is a prospective cohort study aimed at comparing the efficacy and safety of RALOX-HAIC and FOLFOX-HAIC in the treatment of hepatocellular carcinoma. It is planned to enroll 1115 patients with BCLC Stage B or C hepatocellular carcinoma, who will receive FOLFOX-HAIC or RALOX-HAIC treatment.